These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36636443)

  • 21. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Wang DY; Salem JE; Cohen JV; Chandra S; Menzer C; Ye F; Zhao S; Das S; Beckermann KE; Ha L; Rathmell WK; Ancell KK; Balko JM; Bowman C; Davis EJ; Chism DD; Horn L; Long GV; Carlino MS; Lebrun-Vignes B; Eroglu Z; Hassel JC; Menzies AM; Sosman JA; Sullivan RJ; Moslehi JJ; Johnson DB
    JAMA Oncol; 2018 Dec; 4(12):1721-1728. PubMed ID: 30242316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular Health and Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Oren O; Yang EH; Molina JR; Bailey KR; Blumenthal RS; Kopecky SL
    Am J Cardiol; 2020 Jun; 125(12):1920-1926. PubMed ID: 32312493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors.
    Yoshikawa Y; Imamura M; Yamauchi M; Hayes CN; Aikata H; Okamoto W; Miyata Y; Okada M; Hattori N; Sugiyama K; Yoshioka Y; Toratani S; Takechi M; Ichinohe T; Ueda T; Takeno S; Kobayashi T; Ohdan H; Teishima J; Hide M; Nagata Y; Kudo Y; Iida K; Chayama K
    BMC Cancer; 2022 Nov; 22(1):1232. PubMed ID: 36447159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Percutaneous coronary intervention in diabetic versus non-diabetic patients with prior coronary artery bypass grafting: a propensity score matching study.
    Ma X; Dong R; Chen P; Zhao Y; Zeng C; Xin M; Ye Q; Wang J
    BMC Cardiovasc Disord; 2020 Apr; 20(1):159. PubMed ID: 32252636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of Cardiovascular Events in Patients Treated With Immune Checkpoint Inhibitors.
    Laenens D; Yu Y; Santens B; Jacobs J; Beuselinck B; Bechter O; Wauters E; Staessen J; Janssens S; Van Aelst L
    J Clin Oncol; 2022 Oct; 40(29):3430-3438. PubMed ID: 35772044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Arrhythmic events associated with immune checkpoint inhibitors therapy: A real-world study based on the Food and Drug Administration Adverse Event Reporting System database.
    Liu Y; Chen Y; Zeng Z; Liu A
    Cancer Med; 2023 Mar; 12(6):6637-6648. PubMed ID: 36426382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. For patients with prior coronary artery bypass grafting and recurrent myocardial ischemia, percutaneous coronary intervention on bypass graft or native coronary artery?-A 5-year follow-up cohort study.
    Liu R; Liu H; Yuan D; Chen Y; Tang X; Zhang C; Zhu P; Yang T; Zhang Y; Li H; Xu O; Gao R; Xu B; Yuan J
    Clin Cardiol; 2023 Jun; 46(6):680-688. PubMed ID: 37114396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of coronary CTA in coronary bypass patients: a long-term follow-up study.
    Mushtaq S; Andreini D; Pontone G; Bertella E; Bartorelli AL; Conte E; Baggiano A; Annoni A; Formenti A; Trabattoni D; Veglia F; Alamanni F; Fiorentini C; Pepi M
    JACC Cardiovasc Imaging; 2014 Jun; 7(6):580-9. PubMed ID: 24925326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy in patients with autoimmune disease.
    Rakshit S; Molina JR
    J Thorac Dis; 2020 Nov; 12(11):7032-7038. PubMed ID: 33282408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term outcomes after percutaneous coronary intervention relative to bypass surgery in diabetic patients with multivessel coronary artery disease according to clinical presentation.
    Lee YJ; Hong SJ; Kim BK; Shin S; Suh Y; Kim S; Ahn CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    Coron Artery Dis; 2020 Mar; 31(2):174-183. PubMed ID: 31219843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
    Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular Risk Profile, Presentation and Management Outcomes of Patients with Acute Coronary Syndromes after Coronary Artery Bypass Grafting.
    Mahmoud SES; Shahin M; Yousif N; Denegri A; Abo Dahab LH; Lüscher TF
    Curr Probl Cardiol; 2022 Nov; 47(11):101078. PubMed ID: 34902394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of variability in uric acid and future clinical outcomes of patient with coronary artery disease undergoing percutaneous coronary intervention.
    Lim SS; Yang YL; Chen SC; Wu CH; Huang SS; Chan WL; Lin SJ; Chen JW; Chou CY; Pan JP; Charng MJ; Chen YH; Wu TC; Lu TM; Hsu PF; Huang PH; Cheng HM; Huang CC; Sung SH; Lin YJ; Leu HB
    Atherosclerosis; 2020 Mar; 297():40-46. PubMed ID: 32062138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of large periprocedural myocardial infarction on mortality after percutaneous coronary intervention and coronary artery bypass grafting for left main disease: an analysis from the EXCEL trial.
    Ben-Yehuda O; Chen S; Redfors B; McAndrew T; Crowley A; Kosmidou I; Kandzari DE; Puskas JD; Morice MC; Taggart DP; Leon MB; Lembo NJ; Brown WM; Simonton CA; Dressler O; Kappetein AP; Sabik JF; Serruys PW; Stone GW
    Eur Heart J; 2019 Jun; 40(24):1930-1941. PubMed ID: 30919909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.
    Khoja L; Day D; Wei-Wu Chen T; Siu LL; Hansen AR
    Ann Oncol; 2017 Oct; 28(10):2377-2385. PubMed ID: 28945858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease.
    Alexander S; Swami U; Kaur A; Gao Y; Fatima M; Ginn MM; Stein JE; Grivas P; Zakharia Y; Singh N
    Ann Transl Med; 2021 Jun; 9(12):1033. PubMed ID: 34277833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medical costs associated with cardiovascular events among high-risk patients with hyperlipidemia.
    Bonafede MM; Johnson BH; Richhariya A; Gandra SR
    Clinicoecon Outcomes Res; 2015; 7():337-45. PubMed ID: 26089693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes.
    El Khoury P; Roussel R; Fumeron F; Abou-Khalil Y; Velho G; Mohammedi K; Jacob MP; Steg PG; Potier L; Ghaleb Y; Elbitar S; Ragot S; Andreata F; Caligiuri G; Hadjadj S; Boileau C; Marre M; Abifadel M; Varret M; Hansel B
    Diabetes Obes Metab; 2018 Apr; 20(4):943-953. PubMed ID: 29205760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment.
    Abu-Sbeih H; Tran CN; Ge PS; Bhutani MS; Alasadi M; Naing A; Jazaeri AA; Wang Y
    J Immunother Cancer; 2019 May; 7(1):118. PubMed ID: 31053161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Testosterone concentrations and risk of cardiovascular events in androgen-deficient men with atherosclerotic cardiovascular disease.
    Boden WE; Miller MG; McBride R; Harvey C; Snabes MC; Schmidt J; McGovern ME; Fleg JL; Desvigne-Nickens P; Anderson T; Kashyap M; Probstfield JL
    Am Heart J; 2020 Jun; 224():65-76. PubMed ID: 32335402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.